Ordering
Available Variants5 mg
CHA.57018-5mg
Price
€97.60
Available – Dispatch in 14 days
25 mg
CHA.57018-25mg
Price
€403.20
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.57018-5mg | €97.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.57018-25mg | €403.20 |
≥98% (HPLC)
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C20H25NO3 |
|---|---|
| CAS Number | 134234-12-1 |
| Molecular Weight | 327.42 |
| NACRES | NA.77 |
| PubChem Substance ID | 329825120 |
| UNSPSC Code | 12352200 |
| MDL number | MFCD00926469 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
CP-101,606, also known by its CAS number 189894-57-3, is a potent and selective antagonist of the AMPA receptor, a subtype of glutamate receptor. This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of neurological disorders such as epilepsy and ischemic stroke. The AMPA receptor plays a crucial role in excitatory neurotransmission, and excessive activation of this receptor has been implicated in the pathophysiology of various neurological conditions. By blocking the AMPA receptor, CP-101,606 has been shown to exhibit neuroprotective effects in preclinical models, reducing excitotoxicity and promoting neuronal survival. Further research is needed to fully elucidate the therapeutic potential of CP-101,606 and to explore its potential as a treatment for neurological disorders. Its selective mechanism of action makes it an attractive candidate for further development.
